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ABSTRACT
Economic sustainability is of paramount
importance in the rapidly evolving therapeutic
scenario of multiple sclerosis (MS). Glatiramoids
are a class of drugs whose forefather, glatiramer
acetate, has been used as a disease modifying
drug (DMD) in patients with MS for over
20 years. Its patent expired in 2015; new ver-
sions of such drug are nowadays available on
the market, potentially contributing to lower-
ing prices and enhancing a better allocation of
economic resources. In this review, we analyze
the recommendations underlying the approval
of both generic drugs and biosimilars by regu-
latory authorities, and we provide method-
ological tools to contextualize the design of
studies on these new classes of drugs. We
examine in more detail the preclinical and
clinical data of Copemyl, a new member of the
glatiramoid class, focusing on its biological and
immunological properties and illustrating ran-
domized controlled trials that led to its
authorization.
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Glatiramoids are a class of drugs consisting in a
group of heterogenous polypeptide mixtures
comprising four amino acids: L-glutamic acid,
L-alanine, L-lysine, and L-tyrosine [1]. Glatiramer
acetate (GA) is the forefather of this class [1] and
is used as a disease modifying drug (DMD) in
patients with multiple sclerosis (MS) [2]. It was
originally conceived as a synthetic analogue of
myelin basic protein, and initially (and sur-
prisingly) tested to induce experimental
autoimmune encephalomyelitis (EAE), the
experimental model of MS in animals [3]. After
it was shown that, instead of promoting, it
suppressed EAE [4], this molecule was explored
for its possible therapeutic effect, although its
mechanism of action is still not fully known [2].
GA’s mechanism of action encompasses both
anti-inflammatory properties (such as promot-
ing a shift toward a Th2 pattern for reactive
T cells, reducing production of inflammatory
cytokines and enhancing T regulatory cells and
anti-inflammatory cytokines [5–8]) as well as
neuroprotective properties (such as increasing
levels of neurotrophic factors, favoring axonal
protection and possibly reducing gluta-
mate-mediated neurotoxicity [9–11]). Among
biological characteristics of GA, its immuno-
genicity needs to be highlighted for the pur-
poses of this review: in a high proportion of
patients treated with GA a low but significant
titer of anti-GA antibodies (anti-GA) is pro-
duced [12]. Anti-GAs do not interfere with its
efficacy [13].
After GA was tested in several studies over
25 years, two large randomized controlled trials
have been performed testing GA in patients
with MS. In the US glatiramer acetate study [14],
a 29% reduction of the annualized relapse rate
(ARR) favoring GA over placebo was observed,
and in the European–Canadian MRI study [15],
GA-treated patients showed a reduction of
roughly 70% of gadolinium-enhancing (Gd?)
lesions versus placebo. These studies ultimately
led to GA approval as a DMD for MS in 2001.
Fifteen years later, GA’s patent expired,
leading to great interest in the development of
new members of its class. Not all glatiramoids
have shown favorable outcomes in the treat-
ment of MS [1]. In the present review, we will
discuss the regulatory and statistical back-
ground of generic drugs for MS, and we will
present preclinical and clinical evidence of
Copemyl, a new glatiramoid, 20 mg adminis-
tered subcutaneously (sc) daily, and discuss its
equivalence to former GA in terms of efficacy
and safety profile. This article is therefore based
on previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
REGULATION OF GENERIC DRUGS
AND BIOSIMILARS AND THE CASE
OF NON-BIOLOGICAL COMPLEX
DRUGS
A generic medicinal product is defined as a
product which has the same qualitative and
quantitative composition in active substances
and the same pharmaceutical form as the ref-
erence medicinal product, and whose bioe-
quivalence with the reference medicinal
product has been demonstrated by appropriate
bioavailability studies [16].
A biosimilar drug is a drug similar to a bio-
logical drug, i.e., according to the European
Medicines Agency (EMA) definition: ‘‘A product,
the active substance of which is a biological
substance. A biological substance is a substance
that is produced by or extracted from a biolog-
ical source and that needs for its characteriza-
tion and the determination of its quality a
combination of physicochemical–biological
testing, together with the production process
and its control’’ [16].
There are several drugs that are neither clas-
sic small molecules nor biological substances.
These drugs are called non-biological complex
drugs (NBCDs) and consist mainly of thera-
peutic proteins; for instance: liposomal drugs,
iron carbohydrate drugs (‘‘iron-sugars’’), and
drugs belonging to the category of glatiramoids
[17, 18]. The regulation of biosimilars is not
applicable to those products, as they are not the
originator a biological substance. On the other
hand, the classical paradigm for the marketing
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of a generic drug cannot be used for NBCDs
either, mainly because of the complexity of
their structure that impairs classical structure
analysis and pharmacokinetic studies [19–21];
therefore, these products resist regulation of
their own.
The EMA regulates the approval of NBCDs
and their marketing under Article 10(3) of
Directive 2001/83/EC [16]. Article 10(3) does
not impose the new drug and the originator to
be identical, but states that for the approval of
the new version, results of appropriate pre-
clinical testing or clinical trials shall be pro-
vided. Applications for NBCDs will thus rely in
part on the results of preclinical tests and
clinical trials for the reference product, and in
part on new data for the new version of the
drug. Specifically, for new versions of GA such
new data consisted in a randomized three-arm
equivalence trial, including a placebo arm, a
reference GA arm, and an arm treated with the
new GA. Such an approach is in line with what
was proposed in consensus meetings on ther-
apeutic equivalence [17] and was agreed with
the EMA Committee for Medicinal Products for
Human Use (CHMP) [22] as further discussed.
Given the current lack of specific EMA rules for
the management of NBCDs registration, it
should be considered—purely on practical
grounds—that the EMA requires mandatory
centralized procedures for the marketing
authorization of biosimilar drugs. GA is not
considered a biologic and therefore the EU
biologics and biosimilar legislation and regu-
latory pathway is not applicable; in fact, GA
copies were not registered through a central-
ized procedure.
The US Food and Drug Administration
(FDA), unlike EMA regulation, does not require
data from randomized trials to demonstrate
sameness for complex active ingredients, such
as GA, but, in addition to standards applied to
evaluate all generic drug products, it requires
‘‘appropriate information’’ [23]. That further
information for GA consisted mainly of
demonstration of physicochemical equivalence
and equivalent biological and immunological
effects in EAE and were considered sufficient to
approve another version of GA in 2015 [24].
Other glatiramoids purported to be generic GA
are marketed in various countries for the treat-
ment of MS patients [15]. Table 1 summarizes
all different glatiramoids developed so far.
METHODOLOGY OF EQUIVALENCE
TRIALS
Trials to test the clinical efficacy of generic
drugs are necessarily equivalence trials, aimed at
demonstrating that the drug is equivalent to the
original compound. This is the first critical issue
to be taken into account: a non-inferiority
condition is not sufficient and the two drugs
must have the same efficacy. Assessing equiva-
lence of two drugs is generally more difficult
than assessing superiority of one drug over
another, and it requires larger numbers of
patients. The reason for that lies in the defini-
tion of ‘‘equivalence’’. In an equivalence trial
the null hypothesis (that we want to reject) is
that the new drug has an inferior (or a superior)
efficacy than the original drug, while the alter-
native hypothesis is that the new drug has the
same efficacy as the original one [25]. Therefore,
the first step for designing an equivalence trial is
to define what we mean for ‘‘equivalent’’ and
this definition implies the need to set the
so-called equivalence margin. The equivalence
margin is the interval of differences (around
zero) between the new and the original drug
that we can consider clinically not relevant, so
that if the difference detected in the trial lies
within this interval we can declare that the two
drugs are clinically equivalent. It is obvious that
the equivalence margin must be narrow and in
any case narrower than the interval used to
declare superiority [26]. If, for example, in a
study in MS we define a new drug superior to
the standard drug if the former reduces the
relapse rate of 30% more than the latter, the
equivalence margin for two drugs in MS must be
narrower than 30%. We could tolerate, for
example, a difference in relapse rate of 15% as a
difference with no clinical relevance, so that we
could decide to set the equivalence margin as
[-15%, ?15%]. The narrower the interval, the
higher the likelihood that the two drugs are




The synthesis of Copemyl is based on the same
chemistry as the synthesis published for GA,
which results in the complex heterogenous
mixture of random polypeptide chains ranging
from 20 to 200 amino acids with an average of
60 amino acids in length. Consequently, it has
been estimated that any of more than 1029
different potential polypeptide sequences could
be found in GA and in Copemyl [27]. The
manufacturer of Copemyl has performed an
extensive physicochemical and biological char-
acterization program comparing the active
substance present in Copemyl and GA, using a
panel of chemical and biological assays,
including primary structure evaluation, com-
plex structure evaluation, UV spectroscopy, and
capillary isoelectric focusing [27].
Bioequivalence between Copemyl and GA
was tested via several bioassays. Copemyl and
GA were compared in a study evaluating their
effect in modulating gene expression in the
human monocytic THP-1 cell line [28]. In this
study five Copemyl batches were compared to
five GA batches using the GeneChip Human
GenomeU133 Plus 2.0 Array (Thermo Fisher
Scientific Inc.) for analysis of genome-wide
expression, evaluated by microarray after 6 h
exposure of THP-1 cells in vitro to either
Copemyl or GA, showing that the variability of
the modulated genes of the Copemyl batches
was similar to that of the GA batches (specifi-
cally, a total of 52 probe sets were significantly
up- or downregulated by Copemyl and 60 by
GA, compared to vehicle-treated samples. The
variability of the modulated genes of the
Copemyl batches was similar to that of the GA
batches). Another study focused on induction
and activation of glatiramer-specific T cells in
EAE [29]. Mice were immunized with different
batches of either GA or Copemyl, and 10 days
later lymphocytes were obtained from the
draining lymph nodes. The isolated cells were
Table 1 Glatiramoid class members




















Glatopa Sandoz DMD for MS FDA USA No
Escadra Raffo DMD for MS No Argentina No
GTR
polimunol
Synthon DMD for MS No Argentina No
Probioglat Probiomed DMD for MS No Mexico No
Glatimer NATCO DMD for MS No India No
Protiramer TEVA Development halted on basis of




cultured and restimulated with increasing doses
of GA in vitro. GA-specific T cells respond to
in vitro (re)stimulation with increased prolifer-
ation and cytokine—including interleukin-2
(IL-2)—production [30]. IL-2 levels were quan-
tified and the GA-dependent IL-2 secretion
served as a parameter for bioactivity. The
bioactivities ranged between 61.6% and 94.3%
for Copemyl batches and between 56.3% and
94.8% for GA batches, thus confirming analo-
gous immunomodulatory properties. Compar-
ative toxicity studies were performed in rats [27]
to whom Copemyl and GA were administered
subcutaneously by daily injection showing
analogous local reactions and liver effects, with
no difference in frequency and severity of these
effects in rats treated with Copemyl and rats
treated with GA.
CLINICAL DATA
Copemyl was evaluated in patients with MS in
two trials: the 9-month GATE trial [31] and its
15-month extension [32]. The GATE study is a
randomized, double blind active and
placebo-controlled equivalence trial conducted
in 17 countries in 2011–2013 and published in
2015. Patients included were naı̈ve to GA, had
mild to moderate disability [Expanded Disabil-
ity Status Scale (EDSS) [33] of 0–5.5], and had an
active disease (a relapse in the previous year,
and 1–15 Gd? lesions at the screening scan). A
total of 796 patients were randomized to either
Copemyl 20, GA, or placebo, with a ratio of
4.3:4.3:1. The primary endpoint was the num-
ber of Gd? lesions during months 7–9, with an
equivalence margin (EM) tailored considering
results of the former GA Euro-Canadian study
[15], as further discussed. Equivalence required
both statistically significant superiority to pla-
cebo and a 95% CI within predefined equiva-
lence margins for the ratio of Gd? lesions
between Copemyl and GA. Most relevant base-
line characteristics of the randomized patients
(and comparison with the reference GA trials)
are illustrated in Table 2, while Fig. 1 displays
results of the primary endpoint. MRI of Cope-
myl- and GA-treated patients showed a mean
number of Gd? lesions lower than those
administered placebo (ratio 0.488; 95% CI
0.365–0.651; P\0.001), confirming study sen-
sitivity. The estimated ratio of Copemyl to GA
Gd? lesions was 1.095 (95% CI 0.883–1.360),
which fell within the predefined equivalence
margin; therefore, the authors concluded
equivalence between Copemyl and GA. ARR,
though calculated over 9 months, did not differ
in the three arms [0.31 (95% CI 0.20–0.48) for
Copemyl, 0.40 (95% CI 0.26–0.62) for GA, and
0.38 (95% CI 0.22–0.66) for placebo]. In the
three groups mean EDSS score was stable, per-
centage of relapse-free or disease-activity-free
patients did not differ, and no statistically rel-
evant difference in new T2 MRI lesions was
shown. Adverse events (AEs) were evenly
reported in all arms of the study; trademark GA
adverse events such as injection site reactions
(ISR) and immediate post-injection reactions
occurred (PIR) in the same proportion of
patients assigned to GA or Copemyl; namely ISR
were reported by 16.4% of the patients in the
Copemyl arm and 17.4% of those in the GA
arm, while PIR occurred respectively in 6.8% of
the patients for Copemyl and 5% of the patients
for GA.
Patients enrolled in the GATE study were
offered the possibility to continue in a 15--
month open-label extension trial, whose results
have been recently published [32]. Of the 796
patients of the GATE study, 728 agreed to par-
ticipate in the extension and all were treated
with Copemyl. Of these, 670 completed the trial
(92%). For analysis purposes subjects enrolled
into the extension trial were divided into three
arms: patients treated with placebo in the GATE
trial (pbo/Copemyl, n = 81), patients assigned
to GA arm in the GATE trial (GA/Copemyl,
n = 323), and patients randomized to Copemyl
in the GATE trail (Copemyl/Copemyl, n = 324).
MRI conducted at month 12, 18, and 24 from
GATE trial randomization showed a similar
mean number of Gd? lesions for GA/Copemyl
patients and Copemyl/Copemyl patients
(0.6–0.7 in both groups), while pbo/Copemyl
patients showed a higher mean number of Gd?
lesion at the 12-month scan (1.7), declining to
0.7 and 0.9 at months 18 and 24, respectively
(Fig. 2).The change in the number of new T2
lesions was similar in the Copemyl/Copemyl
Neurol Ther
Table 2 GATE trial patients baseline characteristics, compared with baseline characteristics of patients enrolled in the two
pivotal trials of GA

















32.6 (8.7) 33.8 (9) 32.6 (8.6) 34 (7.5) 34.1 (7.4) 34.3 (6.5) 34.6 (6)






5.7 (6) 6.4 (6) 5.5 (5.3) 8.3 (5.5) 7.9 (5.5) 6.6 (5.1) 7.3 (4.9)
Mean number of
relapses in prior 2
years (SD)





Mean (SD) 2.7 (1.2) 2.7 (1.2) 2.6 (1.2) 2.4 (1.2) 2.3 (1.1) 2.4 (1.3) 2.8 (1.2)
Median (range) 2.5 (0–5.5) 2.5 (0–5.5) 2.5 (0–6.0)
Mean number of Gd? lesions (SD) at baseline MRI
Mean (SD) 2.8 (4.1) 2.5 (3.9) 2.5 (3.5) 4.4 (7.1) 4.2 (4.8)
Median (range) 1 (0–28) 1 (0–40) 1 (0–27)
Number of hyperintense lesions in T2-weighted scans
Mean (SD) 47.6 (34.7) 49.6 (31.9) 51.9 (37.7)
Median (range) 42 (2–168) 45 (0–238) 45 (2–363)
Volume of hyperintense lesions in T2-weighted scans (mm3)







Volume of hyperintense lesions in T1-weighted scans (mm3)
Mean (SD) 2091 (4329) 1462 (2741) 1686 (3298)




and GA/Copemyl groups but higher in the pla-
cebo/Copemyl group. Changes in other MRI
parameters (T2 lesion volume, T1 hypointense
lesion volume, and brain volume) were similar
in the Copemyl/Copemyl and GA/Copemyl
groups and larger in the placebo/Copemyl
group. In parallel to what was observed in the
core trial, clinical outcomes, in particular ARR
(0.21, 0.24, and 0.23 for Copemyl/Copemyl,
GA/Copemyl, and placebo/Copemyl, respec-
tively) did not differ among the three groups.
The authors state that these figures are compa-
rable to the 2-year ARR reported in recent clin-
ical trials with GA. Injection-related AEs were
similarly low in the GA/Copemyl group and
Copemyl/Copemyl group (respectively 0.9%
and 1.2% for injection site reactions and 0.9%
and 2.2% for immediate post-injection reac-
tions), while injection site reactions were
reported in 9.9% and immediate post-injection
reactions in 1.2% of patients switching from
placebo to Copemyl. Anti-GA antibodies were
tested throughout the whole duration of both
core and extension study (Fig. 3). During the
9-month double blind study, the anti-GA-posi-
tive proportion of patients and antibody titer
were similar in GA- and Copemyl-treated
patients. Interestingly, when GA patients swit-
ched to Copemyl, their antibody titer remained
equivalent to those of patients originally ran-
domized to Copemyl. These findings allowed
the authors to conclude that efficacy and safety
of Copemyl are maintained over a certain time
and that switching from GA to Copemyl might
be done without loss of efficacy, safety, or
tolerability.
DISCUSSION
Both the GATE study and its extension provide
evidence in support of the equivalence between
Fig. 1 Primary endpoint of the GATE trial [31]: left main
number of Gd? lesions in months 7–9 in the three arms
of the study and right predefined equivalence margins of
n-GA versus GA. This figure is slightly modified in terms
of color and with supplementary notes from [31].
Copyright permission from American Medical Associa-
tion, owner of the rights of the article, was obtained on
June 16, 2017
Fig. 2 Mean number in Gd? new and persisting lesions
in patients enrolled in the open label extension trial of the
GATE study [32]. Groups are divided according to
randomization in double blind GATE trial [31]. This
figure is slightly modified in terms of color and with
supplementary notes from [32]. This work is licensed
under the Creative Commons Attribution-NonCommer-
cial 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc/3.0/ or
send a letter to Creative Commons, P.O. Box 1866,
Mountain View, CA 94042, USA
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Copemyl and GA. In the GATE study, the
equivalent margin (EM), which clearly is of
pivotal importance in such studies, was decided
taking into consideration the results of the
pivotal studies of GA vs placebo. As previously
described, the EM is defined as the largest dif-
ference between the originator and the test drug
that can be judged as clinically acceptable, and
should be no larger than differences observed in
the superiority trial of the originator [26].
Therefore, as in the Euro/Canadian trial in
months 7–9 the mean number of Gd? lesions in
placebo-treated patients was 1.75 times higher
than in GA-treated patients [15], for the GATE
trial the upper limit of the EM was set at 50% of
that value, i.e., 1.375; consequently, the lower
limit was set at 0.727, symmetrically in the log
scale. The value of 50% was chosen because it is
possible to estimate the expected effect on
relapses from an observed effect on MRI lesions,
according to the Sormani equation [34, 35]. An
effect on MRI lesions as relative risk compared
to the originator (RR) of 0.727 (reduction of
27.5%) translates into an effect on relapses as RR
0.825 (reduction of 17.5%); such a difference
was considered non-clinically relevant. Fur-
thermore, in equivalence trials it is crucial that
an assay sensitivity is provided, as it quantifies
to the ability of the trial to detect a difference
between treatments, if such a difference exists
[36].
Authors of the GATE trial state that sample
size calculation (with a dropout rate of 12%
allowed) was performed to ensure a 98% power
to demonstrate study sensitivity, a 92% power
to show equivalence of GA and Copemyl, and a
90% power to show both sensitivity and
equivalence. Results from the GATE trial were
bolstered by the extension trial, in which MRI
results are fully consistent with the hypothesis
of the equivalence between Copemyl and GA.
Furthermore, anti-GA antibodies monitoring
throughout the whole duration of the open
label and the extension trial provided interest-
ing information. The incidence and titer of
anti-GA were comparable with both forms of
GA. Moreover, switching from GA to Copemyl
did not affect anti-GA titers. These results
demonstrate that GA and Copemyl have com-
parable immunogenicity, which is of great
Fig. 3 Mean anti-GA antibody titers in subjects treated
with GA or n-GA in the GATE study (months 0–9) [31]
and in the same groups of patients when treated with
n-GA in open label extension of the trial (months 9–24)
[32]. This figure is slightly modified in terms of color and
with supplementary notes from [32]. This work is licensed
under the Creative Commons Attribution-NonCommer-
cial 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc/3.0/ or
send a letter to Creative Commons, P.O. Box 1866,
Mountain View, CA 94042, USA
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relevance when it comes to evaluating inter-
changeability of complex or biologic drugs
[37, 38]. To our knowledge, this is the only new
version of GA whose immunogenicity has been
evaluated in MS patients.
Even with adequate EM and study sensitiv-
ity, and with immunological evidence in sup-
port, a few drawbacks of the GATE study need to
be addressed: (1) the fact that the primary
endpoint was not a clinical endpoint but an
MRI surrogate of clinical activity, (2) the fact
that over the observation period no differences
in terms of ARR appeared in the three arms of
the study.
The choice of the primary endpoint was de
facto suggested by EMA, after the manufacturers
of Copemyl on several occasions sought EMA
scientific advice as regards the type of new data
required [22]. In fact, the EMA CHMP stated
that MRI measures are acceptable to detect
effect and establish equivalence of two products
containing GA in a shorter study duration, in
cases that the quality data indicate a high level
of similarity [22]. Also, the current CHMP
guideline on multiple sclerosis [39] declares MRI
endpoints to be sufficient for demonstrating
similarity of two products in the context of
biosimilar and generic applications. Anyway,
such endpoints could be perceived as puzzling,
as to date MRI activity has not been the primary
endpoint in any phase III trial in MS. However,
over the last years there has been mounting
evidence of a strong association between MRI
activity and clinical activity. Two meta-analyses
of studies encompassing several DMDs demon-
strated that in MS relapse rate strongly corre-
lates with Gd? lesions, and, more importantly,
that the magnitude of the effect of the drug on
MRI parameters can predict the magnitude of
the benefit in terms of ARR [34, 35]. As far as it
concerns specifically GA, the correlations
between MRI and clinical activity parameters
are particularly robust, stronger than what was
observed, for instance, in interferon-beta
(IFN-b) studies. In fact, trials comparing GA and
IFN-b head to head showed a similar efficacy on
relapses, whereas the effect on MRI activity was
somewhat less pronounced for GA [40–42] and
meta-analysis confirmed these results [43].
These observations were summarized in a paper
published in Nature Reviews Neurology stating
that for equivalence trials on a drug such as
glatiramer acetate, with almost the same mag-
nitude of effect on MRI activity and relapse rate,
an MRI-based approach seems justified [44].
In the GATE trial, the apparent lack of effect
of both GA and Copemyl on relapse rate may
result from multiple factors. The authors sug-
gest that the trial was not designed or powered
to show relapse rate reduction: the placebo
group consisted only of 84 subjects and there-
fore the expected power to demonstrate an ARR
reduction was less than 30%. In addition to
that, the ARR of the placebo group was low,
both at baseline (if compared to the US and the
Euro-Canadian trial) and during the trial. This
observation is not at all unexpected, as it is well
known that ARR in the placebo groups of
phase III trials in MS have consistently
decreased over the years [45]. It suggests that
subjects included in the recent trials have less
aggressive forms of MS than patients included
in the early ones; thus, in order to detect an
effect on ARR, larger sample trials are required
in order to compensate for overall low event
rates. Furthermore, the duration of the GATE
trial was only 9 months. In fact, evidence from a
trial with GA in 481 patients with a first
demyelinating event (CIS) at high risk of
developing MS [46] suggests that the effect of
GA on clinical activity emerges over placebo
after at least 6 months of treatment, suggesting
that a 9-month observation time might have
played a role in not allowing an effect on
relapses to emerge. Anyway, even taking these
considerations into account, the lack of effect
on relapses of both active compounds is some-
how puzzling.
The results of the extension study confirmed
the effect of Copemyl on MRI activity as
patients previously treated with placebo showed
a reduction of T1 Gd-enhancing lesions and T2
lesions at the end of the trial. The effect on MRI
parameters was similar in the two cohorts of
patients previously treated with Copemyl or
GA: in other words, the effect on MRI was
maintained in patients who switched from GA
to Copemyl.
The rate of AEs in both GATE and its exten-
sion trials, namely injection site reaction and
Neurol Ther
post-injection systemic reaction, was lower than
that reported in the trial of GA in CIS men-
tioned above [46] and, although it could prob-
ably have been underestimated, it was even in
patients treated with Copemyl or GA.
CONCLUSIONS
Many medications are currently available for the
treatment of MS, with the clear advantage of
offering many options and the objective to tailor
the therapy to patient characteristics and to
provide higher efficacy for breakthrough disease.
As a result, though, the costs of MS treatment
have increased, as the prices of highly effective
MS DMDs are generally higher than those of
platform therapies. Efforts should be made to
address this question, which potentially limits a
wider access to some therapies. One probable
reason for the skyrocketing costs of MS DMDs is
that DMDs present on the market for decades
have never faced price competition from low-
er-cost equivalent drugs [47]. However, the effect
of the availability of a generic DMD on the costs
of MS therapy is still unclear, because it will
heavily depend upon its price and the extent of
its use, i.e., the extent of how neurologists and
patients are confident that the new drug has
comparable efficacy, safety, and tolerability as
the brand drug. Clinicians will therefore ask to be
reassured on the comparable safety and efficacy
profile of new formulations. A debate is ongoing
on these issues, in particular on two additional
aspects: how definitions of regulatory guidelines
are exhaustive, clear, indisputable [48], and how
new formulations are actually identical to the
original medication, an aspect particularly
important for NBCDs, and especially for glati-
ramoids [18, 49]. Glatiramoids are in fact
immunomodulators, altering pathogenetic
immune mechanisms, but also implying possible
risks such as immunotoxicity, induction of
autoimmune disorders, and lack of efficacy [50].
As glatiramoids are not amenable to conven-
tional methods of demonstrating bioequiva-
lence, according to the same author [50], the only
way to test their safety and efficacy is to produce
robust data from clinical trials. The evidence
presented in this review should reinforce the
confidence of clinicians as far as it concerns
Copemyl, as published data in fact suggest
equivalence of Copemyl and GA on the basis of
immunological and MRI outcomes, thus making
Copemyl a viable option, along with interferons
or teriflunomide among others, for patients suf-
fering with mild to moderate forms of MS. Any-
way, the drawbacks pertaining to clinical data
should be taken into account, and there is a need
for post-marketing evidence comparing the two
compounds in everyday practice and further
confirming their equivalence.
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37. Tóthfalusi L, Endrényi L, Chow SC. Statistical and
regulatory considerations in assessments of inter-
changeability of biological drug products. Eur J
Health Econ. 2014;15:S5–11.
38. Wu LC, Chen F, Lee SL, Raw A, Yu LX. Building
parity between brand and generic peptide products:
regulatory and scientific considerations for quality
of synthetic peptides. Int J Pharm.
2017;518(1–2):320–34.
Neurol Ther
39. EMA/CHMP/771815/2011, Rev. 2.
40. Mikol DD, Barkhof F, Chang P, et al. Comparison of
subcutaneous interferon beta-1a with glatiramer
acetate in patients with relapsing multiple sclerosis
(the REbif vs glatiramer acetate in relapsing MS
disease [REGARD] study): a multicentre, ran-
domised, parallel, open-label trial. Lancet Neurol.
2008;7(10):903–14.
41. O’Connor P, Filippi M, Arnason B, et al. 250 microg
or 500 microg interferon beta-1b versus 20 mg
glatiramer acetate in relapsing-remitting multiple
sclerosis: a prospective, randomised, multicentre
study. Lancet Neurol. 2009;8(10):889–97.
42. Lublin FD, Cofield SS, Cutter GR, et al. Randomized
study combining interferon and glatiramer acetate in
multiple sclerosis. Ann Neurol. 2013;73(3):327–40.
43. La Mantia L, Di Pietrantonj C, Rovaris M, et al.
Interferons-beta versus glatiramer acetate for
relapsing-remitting multiple sclerosis. Cochrane
Database Syst Rev. 2016;24:11.
44. Sørensen PS. Multiple sclerosis. Generic glatiramer
acetate—a step toward cheaper MS drugs? Nat Rev
Neurol. 2016;12(1):5–6.
45. Stellmann JP, Neuhaus A, Herich L et al. Placebo
cohorts in phase-3 MS treatment trials—predictors
for on-trial disease activity 1990–2010 based on a
meta-analysis and individual case data. PLoS One.
2012;7(11):e50347.
46. Comi G, Martinelli V, Rodegher M, et al. Effect of
glatiramer acetate on conversion to clinically defi-
nite multiple sclerosis in patients with clinically
isolated syndrome (PreCISe study): a randomised,
double-blind, placebo-controlled trial. Lancet.
2009;374(9700):1503–11.
47. Bourdette D, Hartung D. Equivalence of glatiramer
acetate generics with branded glatiramer acetate in
efficacy and cost for the treatment of multiple
sclerosis. JAMA Neurol. 2015;72(12):1411–3.
48. Garattini L, Padula A. Why EMA should provide
clearer guidance on the authorization of NBCDs in
generic and hybrid applications. Expert Rev Clin
Pharmacol. 2017;10(3):243–5.
49. Crommelin DJ, de Vlieger JS, Weinstein V, et al.
Different pharmaceutical products need similar
terminology. AAPS J. 2014;16(1):11–4.
50. Nicholas JM. Complex drugs and biologics: scien-
tific and regulatory challenges for follow-on prod-
ucts. Drug Inf J. 2012;46(2):197–206.
Neurol Ther
